Product Code: SR112023A5726
Market Overview:
The global molecular diagnostics market size reached US$ 18.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.4 Billion by 2028, exhibiting a growth rate (CAGR) of 6.5% during 2023-2028.
Molecular diagnostics refers to a set of laboratory tests that sequences the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or cell proteins of an individual to analyze biomarkers of potential diseases. It assists in diagnosing and monitoring infections and diseases, detecting risks, and assessing therapy response. In recent years, molecular diagnostics has rapidly gained traction in oncology, pharmacogenomics, microbiology, infectious diseases, genetic disease screening, and blood screening. With recent advancements, molecular diagnostics has become an essential aspect of patient-tailored interventions and therapeutics, which is escalating its demand across the globe.
Molecular Diagnostics Market Trends:
Molecular diagnostics is widely used by hospitals, laboratories, and research institutes for early detection of diseases, coagulation, and human leukocyte antigen typing. As a result, the rising prevalence of chronic conditions, such as cancer, cardiovascular diseases (CVDs), neurological disorders, and infectious diseases, represents the primary factor driving the market growth. Besides this, the growing geriatric population that is more susceptible to developing numerous medical ailments and the widespread adoption of point-of-care (POC) testing devices are catalyzing the product demand. Additionally, the recent outbreak of coronavirus disease (COVID-19) has accelerated the adoption of molecular diagnostic methods, such as polymerase chain reaction (PCR), for COVID-19 testing. Along with this, several favorable initiatives undertaken by the governing agencies and regulatory authorities of various countries, such as fast approvals of diagnostic products to help curb the spread of the virus, are also propelling the market growth. Furthermore, the leading players are making heavy investments to launch innovative diagnostic devices that offer enhanced accuracy, flexibility, cost-effectiveness, and faster results to expand their product portfolio and gain a competitive edge. Other factors, including the escalating demand for personalized treatment, the emerging trend of preventive medicine, improving healthcare infrastructure, and technological advancements, are also creating a positive market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular diagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology, application and end users.
Breakup by Product:
Reagents and Kits
Instruments
Software and Services
Breakup by Technology:
Polymerase Chain Reactions (PCR)
Hybridization
DNA Sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
Breakup by Application:
Infectious Diseases Diagnostics
Oncology
Genetic Testing
Blood Screening
Others
Breakup by End Users:
Hospitals
Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Diasorin Molecular LLC (DiaSorin), F. Hoffmann-La Roche AG (Roche Holding AG), Hologic Inc., Illumina Inc., Myriad Genetics Inc., Qiagen, Quidel Corporation and Thermo Fisher Scientific.
Key Questions Answered in This Report:
- How has the global molecular diagnostics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global molecular diagnostics market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end users?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global molecular diagnostics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Molecular Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Reagents and Kits
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Software and Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Polymerase Chain Reactions (PCR)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Hybridization
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 DNA Sequencing
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Microarray
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Application
- 8.1 Infectious Diseases Diagnostics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Oncology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Genetic Testing
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Blood Screening
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by End Users
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Agilent Technologies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Becton Dickinson and Company
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Biomerieux SA
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Danaher Corporation
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Diasorin Molecular LLC (DiaSorin S.p.A.)
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 F. Hoffmann-La Roche AG (Roche Holding AG)
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 SWOT Analysis
- 15.3.8 Hologic Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Illumina Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Myriad Genetics Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Qiagen
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Quidel Corporation
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 Thermo Fisher Scientific
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis